Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Randomized, Placebo-Controlled, Double-Blind Study of the Induction of Clinical Response and Remission by QBECO in Subjects With Moderate to Severe Crohn's Disease

NCT01809275 is registered in ClinicalTrials.gov with Qu Biologics Inc. as lead sponsor.

NCT NCT01809275
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01809275 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Randomized, Placebo-Controlled, Double-Blind Study of the Induction of Clinical Response and Remission by QBECO in Subjects With Moderate to Severe Crohn's Disease
Lead sponsor
Qu Biologics Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
March 31, 2013
Completion date
July 31, 2016
Enrollment
68 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease, inflammatory bowel disease